Loading news...
WALTHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life science companies reach and engage healthcare professionals (HCPs) and patients, today announced at CES 2026 a data collaboration with Experian, a leading global data and technology company.
OptimizeRx's Q3 2025 results reinforce my long-term bullish thesis. OPRX demonstrates continued operational momentum, supporting confidence in sustained growth. Recent earnings solidify conviction in the company's strategic positioning and execution.
OptimizeRx Corp. (NASDAQ: OPRX - Get Free Report) insider Edward Stelmakh sold 1,388 shares of OptimizeRx stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $13.51, for a total value of $18,751.88. Following the completion of the transaction, the insider directly owned 126,830 shares of the company's stock,
WALTHAM, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced four new partner agreements that meaningfully expand the Company's in-workflow point-of-care (POC) network, fortify its long-term competitive position, and increase total National Provider Identifier (NPI) reach.
ROKU, AVPT, ETOR, NRIM and OPRX have been added to the Zacks Rank #1 (Strong Buy) List on November 17, 2025.
OptimizeRx Corporation ( OPRX ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Stephen Silvestro - President & CEO Edward Stelmakh - Chief Financial & Strategic Officer Andrew D'Silva - Chief Business Officer Conference Call Participants Ryan Daniels - William Blair & Company L.L.C., Research Division Richard Baldry - ROTH Capital Partners, LLC, Research Division David Grossman - Stifel, Nicolaus & Company, Incorporated, Research Division Eric Martinuzzi - Lake Street Capital Markets, LLC, Research Division Anderson Schock - B.
OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.2 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.12 per share a year ago.
- Q3 revenue of $26.1 million, increased 22% year-over-year- Q3 gross profit increased 30% year-over-year to $17.5 million- Increases full year 2025 guidance to a revenue range between $105 million and $109 million and adjusted EBITDA range between $16 million and $19 million- Introduces 2026 guidance with a revenue range between $118 million and $124 million and adjusted EBITDA range between $19 million and $22 million- Paid off an incremental $2 million in principal from term loan subsequent to the end of Q3 WALTHAM, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today reported results for the three months ended September 30, 2025.
WALTHAM, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, November 6, 2025, at 4:30 p.m. Eastern Time to discuss its results for the third quarter period ended September 30, 2025. The financial results will be issued in a press release prior to the call.
Healthcare stocks quietly outperformed the market in the past 30 days as headlines centered on the government shutdown over the extension of Affordable Care Act tax credits for 2026. The AI in healthcare market is expected to reach $504B by 2032, driven by an aging population, medical data explosion, job shortages, and consumer demand for self-care technology. Healthcare companies are increasingly deploying AI in drug discovery, diagnostics, imagery, robot-assisted surgery, and hospital administration.
OptimizeRx Corporation is evolving from an EHR messaging platform to a clinical data and AI-driven advertising company, leveraging DAAP and MNT technologies. Q2 2025 financials show strong revenue growth, improved margins, and a shift to higher-margin subscription revenues, supporting management's raised guidance for 2025. The Lamar partnership and expanding mid-tier pharma client base diversify revenue streams, reduce risk, and confirm OPRX's strategic pivot to broader advertising markets.
Does OptimizeRx Corp. (OPRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
OPRX posts 55% revenue growth and raises outlook as AI-driven workflow integration fuels leverage and pharma adoption.
WALTHAM, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that management will participate in the 9th Annual Lake Street Capital Best Ideas Growth Conference taking place Thursday, September 11, 2025, in New York, NY.
Strategic Partnership Combines OptimizeRx's Patented Micro-Neighborhood ® Targeting Data with Lamar's Vast Nationwide OOH Network to Strengthen OOH Media for Healthcare Marketing
OPRX, KT and GLDD made it to the Zacks Rank #1 (Strong Buy) growth stocks list on September 5, 2025.
OPRX, PHIN and KT made it to the Zacks Rank #1 (Strong Buy) growth stocks list on September 3, 2025.
Does OptimizeRx Corp. (OPRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
OptimizeRx (OPRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).